Previous 10 | Next 10 |
OCALA, Fla., July 09, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has signed a contract to sponsor a Phase 2a Human Challenge Trial (HCT) to test the company’s drug Ampligen as a potential intranasal antiviral therapy using a human Rhinov...
OCALA, Fla., July 06, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it will host an investor update webcast at 11:00 a.m. Eastern Time on Wednesday, July 14, 2021, to discuss recent accomplishments and upcoming milestones. Investors and other interes...
AIM ImmunoTech (AIM) announces that all subjects have completed treatment in the company’s Phase 1 clinical study to assess the safety, tolerability and biological activity of ampligen as a potential intranasal therapy.Shares up more than 3% premarket.The company said th...
OCALA, Fla., June 21, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that all subjects have completed treatment in the Company’s Phase 1 clinical study to assess the safety, tolerability and biological activity of Ampligen as a potential intranasal ...
OCALA, Fla., June 14, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that its drug Ampligen has been featured in a publication containing state-of-the-art methodologies in the peer-reviewed medical journal Cancers as a potential treatment option fo...
AIM ImmunoTech (AIM) announces two-year extension of its Material Transfer and Research Agreement with Shenzhen Smoore Technology Limited, with the goal of developing Ampligen as a potential inhalation therapy for COVID-19 and other respiratory viral diseases.Initially, AIM entered into&...
OCALA, Fla., May 27, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has entered into a two-year extension of its Material Transfer and Research Agreement with Shenzhen Smoore Technology Limited (Smoore), a subsidiary of Smoore International Holding...
AIM ImmunoTech (AIM) has completed dosing of Cohort 3 in a Phase 1 study to assess the safety, tolerability and biological activity of Ampligen as an intranasal therapy, as a potential prophylaxis or treatment for COVID-19 and other respiratory viral diseases.No serious adverse events were re...
OCALA, Fla., May 26, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has completed dosing of Cohort 3 in a Phase 1 clinical study to assess the safety, tolerability and biological activity of Ampligen as an intranasal therapy, reporting no serious a...
AIM ImmunoTech (AIM): Q1 GAAP EPS of -$0.08 in-line.Revenue of $0.02M (-60.0% Y/Y) misses by $0.33M.Cash, cash equivalents and marketable securities of $63.6M10QPress Release For further details see: AIM ImmunoTech EPS in-line, misses on revenue
News, Short Squeeze, Breakout and More Instantly...
OCALA, Fla., July 24, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the publication of new pre-clinical data concerning the company’s drug Ampligen as part of a combinational therapy in the...
OCALA, Fla., June 10, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced that Thomas K. Equels, MS JD, Chief Executive Officer of AIM will participate in the Virtual Investor Pitch Con...
OCALA, Fla., June 03, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced that Thomas K. Equels, MS JD, Chief Executive Officer of AIM will participate in the Virtual Investor Lunch Break Series ...